A TfRMAb-AβScFv BSA reduced brain amyloid, without cerebral microhemorrhage, in APP-PS1 AD transgenic mice with either twice-weekly IV injections of 1 mg/kg of the BSA (Zhou et al, 2011c), or daily subcutaneous (SQ) injections of 5 mg/kg of the BSA (Sumbria et al, 2013a), as discussed below in Section 3.3.1. Here, APP is linked to Alzheimer disease.